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Epidemiologia i prewencja/Epidemiology and prevention
Introduction
The relationship between blood pressure and the risk
of cardiovascular events is continuous and independent of
other cardiovascular risk factors. It begins at blood
pressure levels (about 110/70 mmHg) commonly classified
as optimal. The higher the blood pressure the higher the
risk of myocardial infarction, heart failure, stroke and
chronic renal failure. Current classification of blood
pressure levels is presented in Table I. It is noteworthy that
the cut-off value to diagnose hypertension in adults
(140/90 mmHg) is the same for all age groups. 
According to the results of the NATPOL III PLUS survey,
in 2002 the prevalence of hypertension in Polish adults
was 29%, 30% were diagnosed as having high normal
blood pressure, while 21% had normal and 20% optimal
pressure levels. The prevalence of hypertension ranges
from a few percent in younger subjects to over 50% in
elderly people, in whom the predominant form is isolated
systolic hypertension. The awareness of hypertension in
the aforementioned survey was 67%. The efficacy of
treatment was very low (12.5%) in Natpol III PLUS, which
was confirmed in another more recent study on a repre-
sentative sample of Polish adults – WOBASZ (14.1%).
The treatment of hypertension aims primarily to
reduce morbidity and mortality from cardiovascular and
renal diseases. The direct purpose is to lower blood
pressure to <140/90 mmHg in the general population
and <130/80 mmHg in patients with diabetes, chronic
renal failure or a history of stroke or myocardial
infarction. Important indirect clinical and therapeutic
aims are the assessment of cardiovascular risk,
searching for secondary causes of hypertension,
normalization or delaying the progress of target organ
damage, control of the accompanying risk factors and
improvement in the quality of life. 
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Category Systolic Diastolic
Optimal <120 and <80
Normal 120-129 and/or 80-84
High normal 130-139 and/or 85-89
Grade 1 hypertension 140-159 and/or 90-99
Grade 2 hypertension 160-179 and/or 100-109
Grade 3 hypertension ≥180 and/or ≥110
Isolated systolic hypertension ≥140 and <90
Table I. Definitions and classification of blood pressure levels (mmHg)
Figure 1. Initiation of antihypertensive treatment
Abbreviations: OD – organ damage, MS – metabolic syndrome, HT – hypertension
Isolated systolic hypertension should be graded (1, 2, 3) according to systolic blood pressure values in the ranges indicated, provided that diastolic
values are <90 mmHg. Grades 1, 2 and 3 correspond to classification in mild, moderate and severe hypertension, respectively. These terms have
now been omitted to avoid confusion with quantification of total cardiovascular risk. 
Blood Pressure (mmHg)
Other risk factors Normal High Normal Grade 1 HT Grade 2 HT Grade 3 HT
OD or disease SBP 120-129 SBP 130-139 SBP 140-159 SBP 160-179 SBP ≥180
or DBP 80-84 or DBP 85-89 or DBP 90-99 or DBP 100-109 or DBP ≥110
No other risk factors No BP intervention No BP intervention Lifestyle changes Lifestyle changes  Lifestyle changes
for several months for several weeks +
then drug treatment then drug treatment Immediate
if BP uncontrolled if BP uncontrolled drug treatment
1-2 risk factors Lifestyle changes Lifestyle changes Lifestyle changes Lifestyle changes  Lifestyle changes
for several weeks for several weeks +
then drug treatment then drug treatment Immediate
if BP uncontrolled if BP uncontrolled drug treatment
≥3 risk factors, Lifestyle changes Lifestyle changes
MS or OD and consider
Lifestyle changes Lifestyle changes Lifestyle changes
drug treatment + Drug treatment + Drug treatment + Immediate
Diabetes Lifestyle changes Lifestyle changes drug treatment
+ Drug treatment
Established CV Lifestyle changes Lifestyle changes Lifestyle changes Lifestyle changes Lifestyle changes
or renal disease + Immediate drug + Immediate drug + Immediate drug + Immediate drug + Immediate drug 
treatment treatment treatment treatment treatment
The therapeutic approach in hypertension should
consider the following factors: systolic and diastolic
blood pressure levels, total cardiovascular risk, the
presence of target organ damage, diabetes and
chronic renal failure and the history of cardiovascular
events. The guide scheme for the initiation of
hypertension treatment due to the recent (2007)
European Society of Hypertension and European
Society of Cardiology (ESH/ESC) guidelines is
presented in Figure 1.
Pharmacological treatment of grade 1 hypertension
should be initiated with one agent while in grades 2 and
3 the combination of two drugs is frequently required.
According to the ESH/ESC 2007 guidelines and the Polish
Society of Hypertension 2003 recommendations, the first
choice antihypertensive agents belong to the following
five major classes: diuretics, beta-blockers, calcium
antagonists, angiotensin convertase enzyme inhibitors
(ACEI) and angiotensin receptor antagonists. A different
standpoint is presented in the American guidelines
(Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation and Treatment of High
Blood Pressure, 2003 [1]) which, based on the results of
the ALLHAT trial, recommend the initiation of
antihypertensive treatment with diuretics. Meanwhile,
according to the British Hypertension Society (2005) the
choice of first-line therapy should be based on patients’
age: ACEIs are preferred <55 years of age, thiazide
diuretics and calcium antagonist after 55 years of age.
Furthermore, in this approach beta-blockers are not
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considered as a first-line therapy. This is based on meta-
analyses suggesting less efficacy of this group of
antihypertensive agents in reducing the risk of stroke
when compared to other main drug classes. 
Long-acting agents with once-a-day administration
should be preferred in the treatment of hypertension.
In the case of inadequate efficacy the dose of a drug
can be increased (when tolerance is good) but not to
the maximum (due to the risk of side effects), the
patient can be switched to an agent from a different
class, or a second drug can be added (preferred
approach) or if necessary even a third one. In
combination, treatment drugs from the same class
(even of different organ protective properties) and with
similar mechanism of action (e.g. vasodilatation) as
well as of similar side effects (except diuretics) should
not be given together. Additionally, when three
antihypertensive agents are used, diuretics are
mandatory. Possible combinations between the main
classes of antihypertensive drugs according to the
ESH/ESC guidelines are presented in Figure 2.
The choice of antihypertensive agent should be
based on constitutional factors (age, race), type of
hypertension (i.g. isolated systolic hypertension), the
presence of additional cardiovascular risk factors,
Accompanying disorder Preferred agents or drugs of choice Less favourable or contraindicated agents
Metabolic syndrome ACEI, angiotensin receptor antagonist, alpha-blocker thiazide diuretic *, beta-blocker*
Isolated systolic hypertension thiazide diuretic, calcium antagonist, ACEI –
Left ventricle hypertrophy ACEI, angiotensin receptor antagonist direct vasodilators
Ischaemic heart disease ACEI*, beta-blocker nifedipine, direct vasodilators
Previous myocardial infarction beta-blocker, ACEI, aldosterone antagonist nifedipine, direct vasodilators
Heart failure ACEI, beta-blocker*, aldosterone antagonist calcium antagonists, alpha-blocker
Aortic dissection beta-blocker*
Peripheral artery disease ACEI, calcium antagonist, alpha-blocker beta-blocker
Previous stroke angiotensin receptor antagonist, ACEI + diuretic beta-blocker
Diabetes ACEI, angiotensin receptor antagonist 
Renal failure ACEI, angiotensin receptor antagonist, loop diuretic ACEI (Pcr >4 mg/dl), angiotensin receptor 
antagonist (Pcr >4 mg/dl), aldosterone antagonists
Asthma or COPD calcium antagonist beta-blocker*, ACEI
angiotensin receptor antagonist 
Gout ACEI thiazide diuretic, beta-blocker
angiotensin receptor antagonist 
Osteoporosis thiazide diuretic –
Prostate hypertrophy alpha-blocker –
Pregnancy alpha-methyldopa, labetalol, dihydralazine ACEI, angiotensin receptor antagonist, 
thiazide diuretic
Surgery beta-blocker centrally acting antagonists of the sympathetic
system, calcium antagonist, diuretic
Table II. 











Figure 2. Possible combinations between some
classes of antihypertensive drugs
The preferred combinations in the general hypertensive population
are represented as thick lines. 
The frames indicate classes of agents proven to be beneficial in
controlled intervention trials.
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target organ damage (heart, kidney, central nervous
system) and concomitant diseases (Table II). In many
cases, when indications and contraindications to use
one agent in a particular patient are mutually exclusive,
the doctor’s decision should analyze the benefit-to-
-harm ratio to choose the best therapeutic option.
Guidelines
1. Arterial hypertension due to its high prevalence,
reaching 29% of Polish adults, inappropriate
detection rate (67%), low effectiveness of treatment
(12%) and strict association with the risk of serious
cardiovascular events and deaths is considered as 
a social disease. Thus blood pressure should be
measured and appropriate advice about the need
for further systematic control should be given
during every doctor visit. The relationship between
blood pressure and cardiovascular risk is continuous
and starts at blood pressure levels classified as
optimal. 
2. Diagnosis of hypertension requires recognition of
elevated blood pressure to at least 140/90 mmHg in
at least two measurements on at least two separate
visits. As cardiovascular risk is associated with
higher systolic as well diastolic blood pressure,
elevation of one of them is sufficient to diagnose
hypertension. High normal blood pressure is
diagnosed when systolic blood pressure is in the
range 130-139 mmHg or diastolic blood pressure is
85-89 mmHg. 
3. Essential hypertension characterized by multifactorial
aetiology and compound pathogenesis, excluding the
possibility to identify and eliminate one specific
cause, represents most cases (90-95%) of
hypertension. However, in a group of patients,
usually younger or representing poor control of
hypertension, secondary causes of hypertension
should be searched for, as their elimination may lead
to persistent blood pressure normalization. 
4. The decision making process in hypertension
should be based on total cardiovascular risk of an
examined patient, which can be assessed using the
SCORE system or if possible by identification of
other risk factors frequently accompanying
hypertension (older age, family history of
premature cardiovascular disease, dyslipidaemia,
impaired glucose tolerance, abdominal obesity,
smoking), evaluation of target organ damage (left
ventricular hypertrophy, carotid wall thickening,
high carotid-femoral pulse wave velocity, low
glomerular filtration rate, slight increase in plasma
creatinine, microalbuminuria) and identification of
hypertension related cardiovascular diseases
(myocardial infarction, heart failure, stroke), renal
insufficiency and diabetes.
5. The main purpose of treatment of hypertensive
patients is to decrease the risk of death and
cardiovascular complications. This requires efficient
blood pressure reduction, appropriate control of
accompanying cardiovascular risk factors and effort
to regress target organ damage. The aim of therapy
is to reduce blood pressure to <140/90 mmHg or, in
patients with diabetes, renal insufficiency, after
stroke or myocardial infarction, <130/80 mmHg. In
elderly patients with isolated systolic hypertension
the possibility to decrease systolic blood pressure
<140 mmHg may be limited by excessive reduction
in diastolic blood pressure (60-70 mmHg); thus the
lowest, well tolerated levels of systolic blood
pressure can be accepted. 
6. Blood pressure normalization in hypertensive
patients is associated with a reduction of the risk of
cerebrovascular events by 30-40%, to the level
found in normotensives, while the reduction of the
risk of coronary events is lower by 1/3. The reason
for this phenomenon and further improvement in
prognosis in reference to coronary events in
hypertensive patients is thoroughly investigated. 
7. Non-pharmacological treatment of hypertension,
frequently called lifestyle modification, should be
implemented immediately in every patient. It also plays
a pivotal role in the prevention of hypertension and
consists of body mass normalization (BMI <25 kg/m2),
maintenance or increase in physical activity level to
regular aerobic exercise at least 30 minutes a day and
for at least 4-5 days a week, smoking cessation,
reduction in salt intake <6 g/day, and moderation of
alcohol consumption to <20 g of ethanol per 24 h in
women and <30 g per 24 h in men. Additionally, in
hypertensive patients an increase in fruit and
vegetable intake and decrease in fat intake (mainly
saturated fat) is recommended. The DASH diet is an
example of a diet with an additional blood pressure
lowering effect. 
8. The pharmacological treatment of hypertension
should be implemented immediately when blood
pressure is equal to or more than 180/110 mmHg.
Over the range of blood pressure values between
140/90 and 180/110 mmHg a decision to start drug
treatment depends on total cardiovascular risk and
the efficacy of nonpharmacological intervention.
Pharmacological treatment is necessary in the case
of high or very high risk of cardiovascular incident
(>20% in 10 years). However, in clinical practice, most
patients with diagnosed hypertension require
pharmacological treatment along with lifestyle
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modification and its prolonged delay may be harmful.
In diabetes antihypertensive drug treatment should
be started in all patients with blood pressure of at
least 130/80 mmHg. 
9. In uncomplicated hypertension in Poland as in most
European countries therapy should be initiated with
agents from five major classes of antihypertensive
drugs: diuretics, beta-blockers, calcium antagonists,
angiotensin convertase enzyme inhibitors, angio-
tensin receptor antagonists, alone or in combi-
nation. Long-acting drugs are preferred. In compli-
cated hypertension, beneficial and harmful effects
of particular agents on metabolism, target organ
damage, cardiovascular and renal complications as
well as other accompanying disorders should be
considered to choose the most appropriate agent in
an individual patient.
10. Monotherapy may be efficient in mild hypertension.
However, in most patients with moderate or severe
hypertension combination treatment should be
prescribed. The low rate of combination treatment
is among the causes of poor blood pressure control.
The preferred combinations of antihypertensive
agents are as follows: 
• angiotensin convertase enzyme inhibitor +
calcium antagonist (organ protection),
• angiotensin convertase enzyme inhibitor or
angiotensin receptor antagonist + thiazide diuretic
(antihypertensive efficacy, secondary prevention of
cerebrovascular events),
• angiotensin convertase enzyme inhibitor + beta-
-blocker (secondary prevention of cardiac
complications),
• angiotensin convertase enzyme inhibitor +
angiotensin receptor antagonist (nephroprotection).
Patients with hypertension over 50 years of age,
with high total cardiovascular risk, diabetes and/or
cardiovascular events in their history usually require
additional therapy with lipid lowering (statins) and
antiplatelet (acetylsalicylic acid in cardiologic dose of
75-150 mg) agents. 
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Tekst w polskiej wersji językowej jest dostępny pod
adresem: www.pfp.edu.pl 
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